GREENWOOD VILLAGE, CO, Feb. 06, 2018 (GLOBE NEWSWIRE) -- Helix TCS, Inc. (OTCQB:HLIX), along with its investment partner Rose Capital, acquired all of the outstanding preferred stock of Bio-Tech Medical Software, Inc. (or BioTrackTHC). This investment represents approximately 18.5% of BioTrackTHC's outstanding capital stock, on an as-converted to common basis. In addition, Helix CEO Zac Venegas will join BioTrackTHC's board."As we continue to execute our strategy of offering integrated operating services to the legal cannabis industry, we are excited to forge a stronger relationship with BioTrackTHC and work towards providing our clients with ways to operate with greater efficiency, security, compliance, and profitability," stated Mr. Venegas.Since its founding in 2015, Helix continues to grow in scale and scope in the legal cannabis industry, operating in the security, transportation and compliance sectors. In 2016, it acquired Cannabase, the industry's oldest electronic wholesale marketplace. "We are impressed with BioTrackTHC's growth and geographic footprint for seed-to-sale systems. Furthering our relationship with BioTrackTHC is ...Full story available on Benzinga.com
